A Response to: Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort.

Ruiz-Antorán, Belén; Sancho-López, Aránzazu; Torres, Ferrán; Fernández-Cruz, Ana

Ruiz-Antorán, Belén; Sancho-López, Aránzazu; Torres, Ferrán; Fernández-Cruz, Ana.

Ruiz-Antorán B; Clinical Pharmacology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain. bruizantoran@gmail.com.
Sancho-López A; Clinical Pharmacology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Torres F; Medical Statistics Core Facility, August Pi i Sunyer Biomedical Research Institute, Hospital Clinic, Barcelona, Spain.
Fernández-Cruz A; Biostatistics Unit, Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain.

Infect Dis Ther ; 10(3): 1811-1813, 2021 Sep.

Article in English | MEDLINE | ID: covidwho-1380501

Keywords

COVID-19; Mortality; SARS-CoV-2; Steroids; Tocilizumab

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: Infect Dis Ther Year: 2021 Document Type: Article Affiliation country: S40121-021-00444-4

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google